This study explores a new treatment for patients with head and neck cancer. It uses a special type of medicine called monoclonal antibodies which are designed to stop cancer cells from growing. The trial tests a medicine called VX15/2503 alone or combined with drugs ipilimumab or nivolumab. The goal is to learn how these drugs affect the immune system and confirm their safety.

• Participants are sorted into six groups with different drug treatments.
• Treatment is delivered through an IV (intravenous) drip, and then surgery is performed between days 17-36.
• Participants must be able to make regular visits, follow the treatment plan, and agree to use birth control during the study.

To qualify, patients need to have Stage I-IVA head and neck cancer that can be surgically removed. They must not have had prior treatment for this cancer. Those with other medical conditions that could interfere with the study or have poor vein access may not be eligible. Being part of this study means attending regular visits and following instructions carefully. The study ensures participants' safety and checks how well the treatments work.